Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03961256 · ClinicalTrials.gov registry record · Phase 2
Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03961256: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03961256 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03961256, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
Researchers are trying to determine if an anti-diabetes medication, called Exenatide SR, is well tolerated in kidney transplant patients with elevated blood glucose levels, and if it's effective in preventing diabetes.
Interventions
- DRUG Exenatide SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-05-09 |
| Est. Completion | 2021-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03961256
The ClinicalTrials.gov registry entry for NCT03961256 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exenatide SR is the first listed.
NCT03961256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03961256 about?
NCT03961256 is a clinical study titled "Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation". Researchers are trying to determine if an anti-diabetes medication, called Exenatide SR, is well tolerated in kidney transplant patients with elevated blood glucose levels, and if it's effective in preventing diabetes.
What is the current status of trial NCT03961256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2019-05-09. Estimated completion is 2021-10-18.
What interventions are being tested in trial NCT03961256?
The interventions under investigation include: Exenatide SR (DRUG).
Who is sponsoring clinical trial NCT03961256?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.